Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014.
Dallas, TX (PRWEB) July 11, 2014
Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).
However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.
Complete report is available at http://www.chinamarketresearchreports.com/114862.html.
Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.
Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.
Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014. In June 2014, Wuhan Zhongyuan Ruide Biological Product Co., Ltd. (100% controlled by Humanwell Healthcare (Group) Co., Ltd.)’s plasmapheresis center in Chibi was approved to collect plasma; In May 2014, Hualan Bio’s plasma station in Hua County, Henan Province was approved to be set up; In April 2014, Hebei Da'an Pharmaceutical (90% stake controlled by Walvax Biotechnology Co., Ltd.) carried out on-site GMP compliance certification for its plasma station in Wei County; At the end of 2013, Guangdong Shuanglin Bio-pharmacy’s plasma stations in Xi County and Jiang County of Shanxi were completed.
Purchase a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114862.
In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations.
China Blood Products Industry Report, 2014-2017 focuses on the following:
- Market size, plasma volume, distribution of plasma stations, supply and demand, import and export, etc. of China blood products industry;
- Competitive landscape, policy environment, development forecast, etc. of China blood products industry;
- Supply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, Human Immunoglobulin (pH4) for Intravenous Injection, blood coagulation factor and human rabies immunoglobulin (HRIG).
- Operation, blood products business and development prospects of 12 major Chinese blood products companies.
Few Points from Table of Contents
4. Major Chinese Manufacturers
4.1 China Biologic Products Inc.
4.2 Hualan Biological Engineering Inc.
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd.
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.10 Green Cross
4.11 Humanwell Healthcare Group Co., Ltd.
4.12 Walvax Biotechnology Co, Ltd.
Browse more reports on Life Sciences Industry at http://www.chinamarketresearchreports.com/cat/life-sciences.html.
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/ .) is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.